{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T22:23:47Z","timestamp":1781735027051,"version":"3.54.5"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"\u201cAldo Ravelli\u201d Center for Neurotechnology and Experimental Brain Therapeutics"},{"name":"Fondazione Veronesi, Milano, Italy"},{"name":"Universit\u00e0 dell'Insubria, Varese, Italy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s12035-020-01931-4","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T04:34:40Z","timestamp":1589949280000},"page":"2934-2943","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Simple and Complex Sugars in Parkinson\u2019s Disease: a Bittersweet Taste"],"prefix":"10.1007","volume":"57","author":[{"given":"Aida","family":"Zulueta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Mingione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Signorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Caretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Ghidoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0194-6933","authenticated-orcid":false,"given":"Marco","family":"Trinchera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"1931_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.neurobiolaging.2019.03.014","volume":"80","author":"J Wihan","year":"2019","unstructured":"Wihan J, Grosch J, Kalinichenko LS, M\u00fcller CP, Winkler J, Kohl Z (2019) Layer-specific axonal degeneration of serotonergic fibers in the prefrontal cortex of aged A53T \u03b1-synuclein\u2013expressing mice. Neurobiol Aging 80:29\u201337","journal-title":"Neurobiol Aging"},{"issue":"3","key":"1931_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/jnc.13253","volume":"135","author":"J Deusser","year":"2015","unstructured":"Deusser J, Schmidt S, Ettle B, Pl\u00f6tz S, Huber S, M\u00fcller CP, Masliah E, Winkler J et al (2015) Serotonergic dysfunction in the A53T alpha-synuclein mouse model of Parkinson\u2019s disease. J Neurochem 135(3):589\u2013597","journal-title":"J Neurochem"},{"key":"1931_CR3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.nbd.2015.10.021","volume":"85","author":"Z Kohl","year":"2016","unstructured":"Kohl Z, Ben Abdallah N, Vogelgsang J, Tischer L, Deusser J, Amato D, Anderson S, M\u00fcller CP et al (2016) Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC \u03b1-synuclein transgenic rat model of Parkinson\u2019s disease. Neurobiol Dis 85:206\u2013217","journal-title":"Neurobiol Dis"},{"issue":"1","key":"1931_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.neuron.2018.09.014","volume":"100","author":"S Nuber","year":"2018","unstructured":"Nuber S, Rajsombath M, Minakaki G, Winkler J, M\u00fcller CP, Ericsson M, Caldarone B, Dettmer U et al (2018) Abrogating native \u03b1-Synuclein tetramers in mice causes a L-Dopa-responsive motor syndrome closely resembling Parkinson\u2019s disease. Neuron 100(1):75\u201390 e5","journal-title":"Neuron"},{"issue":"1","key":"1931_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.14108","volume":"27","author":"R Balestrino","year":"2020","unstructured":"Balestrino R, Schapira AHV (2020) Parkinson disease. Eur J Neurol 27(1):27\u201342","journal-title":"Eur J Neurol"},{"issue":"2","key":"1931_CR6","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1152\/physrev.00033.2013","volume":"94","author":"RL Schnaar","year":"2014","unstructured":"Schnaar RL, Gerardy-Schahn R, Hildebrandt H (2014) Sialic acids in the brain: Gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration. Physiol Rev 94(2):461\u2013518","journal-title":"Physiol Rev"},{"key":"1931_CR7","first-page":"589\u2013601","volume":"68\u201369","author":"F Heindryckx","year":"2018","unstructured":"Heindryckx F, Li JP (2018) Role of proteoglycans in neuro-inflammation and central nervous system fibrosis. Matrix Biol 68\u201369:589\u2013601","journal-title":"Matrix Biol"},{"issue":"1","key":"1931_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1042\/BST20180330","volume":"47","author":"S Iqbal","year":"2019","unstructured":"Iqbal S, Ghanimi Fard M, Everest-Dass A, Packer NH, Parker LM (2019) Understanding cellular glycan surfaces in the central nervous system. Biochem Soc Trans 47(1):89\u2013100","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"1931_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.bbagen.2013.08.017","volume":"1840","author":"G Lauc","year":"2014","unstructured":"Lauc G, Vojta A, Zoldos V (2014) Epigenetic regulation of glycosylation is the quantum mechanics of biology. Biochim Biophys Acta 1840(1):65\u201370","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"1931_CR10","first-page":"484","volume":"3","author":"M Trinchera","year":"2014","unstructured":"Trinchera M, Zulueta A, Caretti A, Dall'Olio F (2014) Control of glycosylation-related genes by DNA methylation: the intriguing case of the B3GALT5 gene and its distinct promoters. Biology (Basel) 3(3):484\u2013497","journal-title":"Biology (Basel)"},{"issue":"2","key":"1931_CR11","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1096\/fj.13-236273","volume":"28","author":"A Zulueta","year":"2014","unstructured":"Zulueta A, Caretti A, Signorelli P, Dall'olio F, Trinchera M (2014) Transcriptional control of the B3GALT5 gene by a retroviral promoter and methylation of distant regulatory elements. FASEB J 28(2):946\u2013955","journal-title":"FASEB J"},{"issue":"1","key":"1931_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/glycob\/cww086","volume":"27","author":"A Varki","year":"2017","unstructured":"Varki A (2017) Biological roles of glycans. Glycobiology 27(1):3\u201349","journal-title":"Glycobiology"},{"key":"1931_CR13","doi-asserted-by":"publisher","unstructured":"Moll T, Shaw PJ, Cooper-Knock J (2019) Disrupted glycosylation of lipids and proteins is a cause of neurodegeneration. Brain. https:\/\/doi.org\/10.1093\/brain\/awz358","DOI":"10.1093\/brain\/awz358"},{"issue":"6","key":"1931_CR14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.tig.2018.03.002","volume":"34","author":"BG Ng","year":"2018","unstructured":"Ng BG, Freeze HH (2018) Perspectives on glycosylation and its congenital disorders. Trends Genet 34(6):466\u2013476","journal-title":"Trends Genet"},{"issue":"4","key":"1931_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ymgme.2018.06.014","volume":"124","author":"M Trinchera","year":"2018","unstructured":"Trinchera M, Parini R, Indellicato R, Domenighini R, Dall\u2019Olio F (2018) Diseases of ganglioside biosynthesis: An expanding group of congenital disorders of glycosylation. Mol Genet Metab 124(4):230\u2013237","journal-title":"Mol Genet Metab"},{"key":"1931_CR16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1749-6632.1998.tb09688.x","volume":"845","author":"JS Schneider","year":"1998","unstructured":"Schneider JS (1998) GM1 ganglioside in the treatment of Parkinson\u2019s disease. Ann N Y Acad Sci 845:363\u2013373","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"1931_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3109\/00207454.2014.996640","volume":"126","author":"XH Ba","year":"2016","unstructured":"Ba XH (2016) Therapeutic effects of GM1 on Parkinson\u2019s disease in rats and its mechanism. Int J Neurosci 126(2):163\u2013167","journal-title":"Int J Neurosci"},{"issue":"1","key":"1931_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/glia.10047","volume":"38","author":"JK Ryu","year":"2002","unstructured":"Ryu JK, Shin WH, Kim J, Joe EH, Lee YB, Cho KG, Oh YJ, Kim SU et al (2002) Trisialoganglioside GT1b induces in vivo degeneration of nigral dopaminergic neurons: role of microglia. Glia 38(1):15\u201323","journal-title":"Glia"},{"issue":"1","key":"1931_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1034\/j.1600-0404.2002.01240.x","volume":"106","author":"M Zappia","year":"2002","unstructured":"Zappia M, Crescibene L, Bosco D, Arabia G, Nicoletti G, Bagala A, Bastone L, Napoli ID et al (2002) Anti-GM1 ganglioside antibodies in Parkinson\u2019s disease. Acta Neurol Scand 106(1):54\u201357","journal-title":"Acta Neurol Scand"},{"key":"1931_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neuroscience.2018.11.034","volume":"397","author":"RH Bhuiyan","year":"2019","unstructured":"Bhuiyan RH, Ohmi Y, Ohkawa Y, Zhang P, Takano M, Hashimoto N, Okajima T, Furukawa K (2019) Loss of enzyme activity in mutated B4GALNT1 gene products in patients with hereditary spastic paraplegia results in relatively mild neurological disorders: Similarity with phenotypes of B4galnt1 knockout mice. Neuroscience 397:94\u2013106","journal-title":"Neuroscience"},{"issue":"10","key":"1931_CR21","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1002\/jnr.23090","volume":"90","author":"G Wu","year":"2012","unstructured":"Wu G, Lu ZH, Kulkarni N, Ledeen RW (2012) Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans. J Neurosci Res 90(10):1997\u20132008","journal-title":"J Neurosci Res"},{"key":"1931_CR22","doi-asserted-by":"publisher","first-page":"106272","DOI":"10.1016\/j.bpc.2019.106272","volume":"255","author":"F Perissinotto","year":"2019","unstructured":"Perissinotto F, Rondelli V, Parisse P, Tormena N, Zunino A, Almasy L, Merkel DG, Bottyan L et al (2019) GM1 Ganglioside role in the interaction of alpha-synuclein with lipid membranes: Morphology and structure. Biophys Chem 255:106272","journal-title":"Biophys Chem"},{"issue":"6","key":"1931_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199189","volume":"13","author":"JS Schneider","year":"2018","unstructured":"Schneider JS (2018) Altered expression of genes involved in ganglioside biosynthesis in substantia nigra neurons in Parkinson\u2019s disease. PLoS One 13(6):e0199189","journal-title":"PLoS One"},{"key":"1931_CR24","doi-asserted-by":"publisher","first-page":"175909141878188","DOI":"10.1177\/1759091418781889","volume":"10","author":"TN Seyfried","year":"2018","unstructured":"Seyfried TN, Choi H, Chevalier A, Hogan D, Akgoc Z, Schneider JS (2018) Sex-related abnormalities in substantia nigra lipids in Parkinson\u2019s disease. ASN Neuro 10:1759091418781889","journal-title":"ASN Neuro"},{"issue":"13","key":"1931_CR25","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.18632\/aging.102072","volume":"11","author":"L Ma","year":"2019","unstructured":"Ma L, Song J, Sun X, Ding W, Fan K, Qi M, Xu Y, Zhang W (2019) Role of microtubule-associated protein 6 glycosylated with gal-(beta-1,3)-GalNAc in Parkinson\u2019s disease. Aging (Albany NY) 11(13):4597\u20134610","journal-title":"Aging (Albany NY)"},{"issue":"10","key":"1931_CR26","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1016\/j.bbagen.2017.07.005","volume":"1861","author":"K Hoshi","year":"2017","unstructured":"Hoshi K, Matsumoto Y, Ito H, Saito K, Honda T, Yamaguchi Y, Hashimoto Y (2017) A unique glycan-isoform of transferrin in cerebrospinal fluid: A potential diagnostic marker for neurological diseases. Biochim Biophys Acta Gen Subj 1861(10):2473\u20132478","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"1931_CR27","doi-asserted-by":"crossref","unstructured":"Varadi C, Nehez K, Hornyak O, Viskolcz B, Bones J (2019) Serum N-Glycosylation in Parkinson\u2019s disease: a novel approach for potential alterations. Molecules 24(12):E2220","DOI":"10.3390\/molecules24122220"},{"issue":"5","key":"1931_CR28","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/glycob\/cwx022","volume":"27","author":"AC Russell","year":"2017","unstructured":"Russell AC, Simurina M, Garcia MT, Novokmet M, Wang Y, Rudan I, Campbell H, Lauc G et al (2017) The N-glycosylation of immunoglobulin G as a novel biomarker of Parkinson\u2019s disease. Glycobiology 27(5):501\u2013510","journal-title":"Glycobiology"},{"issue":"6","key":"1931_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000318","volume":"17","author":"M Birol","year":"2019","unstructured":"Birol M, Wojcik SP, Miranker AD, Rhoades E (2019) Identification of N-linked glycans as specific mediators of neuronal uptake of acetylated alpha-synuclein. PLoS Biol 17(6):e3000318","journal-title":"PLoS Biol"},{"issue":"2","key":"1931_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bbapap.2008.09.025","volume":"1794","author":"J Kulathingal","year":"2009","unstructured":"Kulathingal J, Ko LW, Cusack B, Yen SH (2009) Proteomic profiling of phosphoproteins and glycoproteins responsive to wild-type alpha-synuclein accumulation and aggregation. Biochim Biophys Acta 1794(2):211\u2013224","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"1931_CR31","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.nbd.2009.09.002","volume":"36","author":"D Afonso-Oramas","year":"2009","unstructured":"Afonso-Oramas D, Cruz-Muros I, Alvarez dela Rosa D, Abreu P, Giraldez T, Castro-Hernandez J, Salas-Hernandez J, Lanciego JL et al (2009) Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease. Neurobiol Dis 36(3):494\u2013508","journal-title":"Neurobiol Dis"},{"key":"1931_CR32","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3389\/fphar.2019.01661","volume":"10","author":"T Walimbe","year":"2019","unstructured":"Walimbe T, Panitch A (2019) Proteoglycans in biomedicine: resurgence of an underexploited class of ECM molecules. Front Pharmacol 10:1661","journal-title":"Front Pharmacol"},{"issue":"12","key":"1931_CR33","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/glycob\/cwj014","volume":"15","author":"IH Liu","year":"2005","unstructured":"Liu IH, Uversky VN, Munishkina LA, Fink AL, Halfter W, Cole GJ (2005) Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation. Glycobiology 15(12):1320\u20131331","journal-title":"Glycobiology"},{"issue":"1","key":"1931_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116641","volume":"10","author":"S Lehri-Boufala","year":"2015","unstructured":"Lehri-Boufala S, Ouidja MO, Barbier-Chassefiere V, Henault E, Raisman-Vozari R, Garrigue-Antar L, Papy-Garcia D, Morin C (2015) New roles of glycosaminoglycans in alpha-synuclein aggregation in a cellular model of Parkinson disease. PLoS One 10(1):e0116641","journal-title":"PLoS One"},{"issue":"34","key":"1931_CR35","doi-asserted-by":"publisher","first-page":"12975","DOI":"10.1074\/jbc.RA118.004267","volume":"293","author":"S Mehra","year":"2018","unstructured":"Mehra S, Ghosh D, Kumar R, Mondal M, Gadhe LG, Das S, Anoop A, Jha NN et al (2018) Glycosaminoglycans have variable effects on alpha-synuclein aggregation and differentially affect the activities of the resulting amyloid fibrils. J Biol Chem 293(34):12975\u201312991","journal-title":"J Biol Chem"},{"issue":"9","key":"1931_CR36","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1074\/mcp.RA118.000680","volume":"17","author":"R Raghunathan","year":"2018","unstructured":"Raghunathan R, Polinski NK, Klein JA, Hogan JD, Shao C, Khatri K, Leon D, McComb ME et al (2018) Glycomic and proteomic changes in aging brain Nigrostriatal pathway. Mol Cell Proteomics 17(9):1778\u20131787","journal-title":"Mol Cell Proteomics"},{"issue":"1","key":"1931_CR37","doi-asserted-by":"publisher","first-page":"5692","DOI":"10.1038\/s41598-018-24079-7","volume":"8","author":"S Choudhary","year":"2018","unstructured":"Choudhary S, Save SN, Vavilala SL (2018) Unravelling the inhibitory activity of Chlamydomonas reinhardtii sulfated polysaccharides against alpha-Synuclein fibrillation. Sci Rep 8(1):5692","journal-title":"Sci Rep"},{"issue":"6","key":"1931_CR38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/jb\/mvz064","volume":"166","author":"GP Panigrahi","year":"2019","unstructured":"Panigrahi GP, Rane AR, Vavilala SL, Choudhary S (2019) Deciphering the anti-Parkinson\u2019s activity of sulphated polysaccharides from Chlamydomonas reinhardtii on the alpha-Synuclein mutants A30P, A53T, E46K, E57K and E35K. J Biochem 166(6):463\u2013474","journal-title":"J Biochem"},{"issue":"7","key":"1931_CR39","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nrm.2017.22","volume":"18","author":"X Yang","year":"2017","unstructured":"Yang X, Qian K (2017) Protein O-GlcNAcylation: emerging mechanisms and functions. Nat Rev Mol Cell Biol 18(7):452\u2013465","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"1931_CR40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13041-017-0311-1","volume":"10","author":"WY Wani","year":"2017","unstructured":"Wani WY, Ouyang X, Benavides GA, Redmann M, Cofield SS, Shacka JJ, Chatham JC, Darley-Usmar V et al (2017) O-GlcNAc regulation of autophagy and alpha-synuclein homeostasis; implications for Parkinson\u2019s disease. Mol Brain 10(1):32","journal-title":"Mol Brain"},{"issue":"5","key":"1931_CR41","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1073\/pnas.1808845116","volume":"116","author":"PM Levine","year":"2019","unstructured":"Levine PM, Galesic A, Balana AT, Mahul-Mellier AL, Navarro MX, De Leon CA, Lashuel HA, Pratt MR (2019) Alpha-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease. Proc Natl Acad Sci U S A 116(5):1511\u20131519","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"1931_CR42","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med 361(17):1651\u20131661","journal-title":"N Engl J Med"},{"issue":"11","key":"1931_CR43","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1002\/mds.26802","volume":"31","author":"YC Wong","year":"2016","unstructured":"Wong YC, Krainc D (2016) Lysosomal trafficking defects link Parkinson\u2019s disease with Gaucher\u2019s disease. Mov Disord 31(11):1610\u20131618","journal-title":"Mov Disord"},{"key":"1931_CR44","doi-asserted-by":"crossref","unstructured":"Riboldi GM, Di Fonzo AB (2019) GBA, Gaucher Disease, and Parkinson\u2019s disease: from genetic to clinic to new therapeutic approaches. Cells 8(4):E364","DOI":"10.3390\/cells8040364"},{"issue":"3","key":"1931_CR45","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/ene.13837","volume":"26","author":"S Mullin","year":"2019","unstructured":"Mullin S, Hughes D, Mehta A, Schapira AHV (2019) Neurological effects of glucocerebrosidase gene mutations. Eur J Neurol 26(3):388\u2013e29","journal-title":"Eur J Neurol"},{"issue":"1","key":"1931_CR46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","volume":"4","author":"FM Platt","year":"2018","unstructured":"Platt FM, d'Azzo A, Davidson BL, Neufeld EF, Tifft CJ (2018) Lysosomal storage diseases. Nat Rev Dis Primers 4(1):27","journal-title":"Nat Rev Dis Primers"},{"issue":"19","key":"1931_CR47","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1111\/febs.14393","volume":"285","author":"ME Gegg","year":"2018","unstructured":"Gegg ME, Schapira AHV (2018) The role of glucocerebrosidase in Parkinson disease pathogenesis. FEBS J 285(19):3591\u20133603","journal-title":"FEBS J"},{"issue":"10","key":"1931_CR48","first-page":"1696","volume":"27","author":"VE Papadopoulos","year":"2018","unstructured":"Papadopoulos VE, Nikolopoulou G, Antoniadou I, Karachaliou A, Arianoglou G, Emmanouilidou E, Sardi SP, Stefanis L et al (2018) Modulation of beta-glucocerebrosidase increases alpha-synuclein secretion and exosome release in mouse models of Parkinson\u2019s disease. Hum Mol Genet 27(10):1696\u20131710","journal-title":"Hum Mol Genet"},{"issue":"2","key":"1931_CR49","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.tem.2018.11.003","volume":"30","author":"G Lin","year":"2019","unstructured":"Lin G, Wang L, Marcogliese PC, Bellen HJ (2019) Sphingolipids in the pathogenesis of Parkinson\u2019s disease and parkinsonism. Trends Endocrinol Metab 30(2):106\u2013117","journal-title":"Trends Endocrinol Metab"},{"key":"1931_CR50","doi-asserted-by":"crossref","unstructured":"Indellicato R, Trinchera M (2019) The link between Gaucher disease and Parkinson\u2019sdDisease sheds light on old and novel disorders of sphingolipid metabolism. Int J Mol Sci 20(13):E3304","DOI":"10.3390\/ijms20133304"},{"issue":"8","key":"1931_CR51","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/mds.27393","volume":"33","author":"S Pchelina","year":"2018","unstructured":"Pchelina S, Baydakova G, Nikolaev M, Senkevich K, Emelyanov A, Kopytova A, Miliukhina I, Yakimovskii A et al (2018) Blood lysosphingolipids accumulation in patients with Parkinson\u2019s disease with glucocerebrosidase 1 mutations. Mov Disord 33(8):1325\u20131330","journal-title":"Mov Disord"},{"issue":"1","key":"1931_CR52","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/15548627.2018.1509818","volume":"15","author":"H Li","year":"2019","unstructured":"Li H, Ham A, Ma TC, Kuo SH, Kanter E, Kim D, Ko HS, Quan Y et al (2019) Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations. Autophagy 15(1):113\u2013130","journal-title":"Autophagy"},{"issue":"1","key":"1931_CR53","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13023-019-1079-4","volume":"14","author":"M Wilke","year":"2019","unstructured":"Wilke M, Dornelles AD, Schuh AS, Vairo FP, Basgalupp SP, Siebert M, Nalin T, Piltcher OB et al (2019) Evaluation of the frequency of non-motor symptoms of Parkinson\u2019s disease in adult patients with Gaucher disease type 1. Orphanet J Rare Dis 14(1):103","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"1931_CR54","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/jnnp-2019-320394","volume":"90","author":"M Avenali","year":"2019","unstructured":"Avenali M, Toffoli M, Mullin S, McNeil A, Hughes DA, Mehta A, Blandini F, Schapira AHV (2019) Evolution of prodromal parkinsonian features in a cohort of GBA mutation-positive individuals: a 6-year longitudinal study. J Neurol Neurosurg Psychiatry 90(10):1091\u20131097","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1931_CR55","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13024-019-0339-z","volume":"14","author":"M Huebecker","year":"2019","unstructured":"Huebecker M, Moloney EB, van der Spoel AC, Priestman DA, Isacson O, Hallett PJ, Platt FM (2019) Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson\u2019s disease. Mol Neurodegener 14(1):40","journal-title":"Mol Neurodegener"},{"issue":"1","key":"1931_CR56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/mds.27583","volume":"34","author":"F Blandini","year":"2019","unstructured":"Blandini F, Cilia R, Cerri S, Pezzoli G, Schapira AHV, Mullin S, Lanciego JL (2019) Glucocerebrosidase mutations and synucleinopathies: toward a model of precision medicine. Mov Disord 34(1):9\u201321","journal-title":"Mov Disord"},{"key":"1931_CR57","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cca.2019.03.1627","volume":"495","author":"S Paciotti","year":"2019","unstructured":"Paciotti S, Gatticchi L, Beccari T, Parnetti L (2019) Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies. Clin Chim Acta 495:13\u201324","journal-title":"Clin Chim Acta"},{"issue":"22","key":"1931_CR58","doi-asserted-by":"publisher","first-page":"10338","DOI":"10.18632\/aging.102460","volume":"11","author":"C Moren","year":"2019","unstructured":"Moren C, Juarez-Flores DL, Chau KY, Gegg M, Garrabou G, Gonzalez-Casacuberta I, Guitart-Mampel M, Tolosa E et al (2019) GBA mutation promotes early mitochondrial dysfunction in 3D neurosphere models. Aging (Albany NY) 11(22):10338\u201310355","journal-title":"Aging (Albany NY)"},{"issue":"11","key":"1931_CR59","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1073\/pnas.1818411116","volume":"116","author":"R Romero","year":"2019","unstructured":"Romero R, Ramanathan A, Yuen T, Bhowmik D, Mathew M, Munshi LB, Javaid S, Bloch M et al (2019) Mechanism of glucocerebrosidase activation and dysfunction in Gaucher disease unraveled by molecular dynamics and deep learning. Proc Natl Acad Sci U S A 116(11):5086\u20135095","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1931_CR60","doi-asserted-by":"crossref","unstructured":"Lerche S, Wurster I, Roeben B, Zimmermann M, Riebenbauer B, Deuschle C, Hauser AK, Schulte C et al (2019) Parkinson\u2019s disease: Glucocerebrosidase 1 mutation severity is associated with CSF alpha-synuclein profiles. Mov Disord 35(3):495\u2013499","DOI":"10.1002\/mds.27884"},{"issue":"3","key":"1931_CR61","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/mdc3.12743","volume":"6","author":"E Hertz","year":"2019","unstructured":"Hertz E, Thornqvist M, Holmberg B, Machaczka M, Sidransky E, Svenningsson P (2019) First Clinicogenetic description of Parkinson\u2019s disease related to GBA mutation S107L. Mov Disord Clin Pract 6(3):254\u2013258","journal-title":"Mov Disord Clin Pract"},{"key":"1931_CR62","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.parkreldis.2019.01.030","volume":"63","author":"C Velez-Pardo","year":"2019","unstructured":"Velez-Pardo C, Lorenzo-Betancor O, Jimenez-Del-Rio M, Moreno S, Lopera F, Cornejo-Olivas M, Torres L, Inca-Martinez M et al (2019) The distribution and risk effect of GBA variants in a large cohort of PD patients from Colombia and Peru. Parkinsonism Relat Disord 63:204\u2013208","journal-title":"Parkinsonism Relat Disord"},{"key":"1931_CR63","doi-asserted-by":"crossref","unstructured":"Mahungu AC, Anderson DG, Rossouw AC, van Coller R, Carr JA, Ross OA, Bardien S (2019) Screening of the glucocerebrosidase (GBA) gene in south Africans of African ancestry with Parkinson\u2019s disease. Neurobiol Aging","DOI":"10.1016\/j.neurobiolaging.2019.12.011"},{"key":"1931_CR64","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/mds.27971","volume":"35","author":"S Ji","year":"2020","unstructured":"Ji S, Wang C, Qiao H, Gu Z, Gan-Or Z, Fon EA, Chan P (2020) Decreased penetrance of Parkinson\u2019s disease in elderly carriers of Glucocerebrosidase gene L444P\/R mutations: a community-based 10-year longitudinal study. Mov Disord 35:672\u2013678","journal-title":"Mov Disord"},{"issue":"4","key":"1931_CR65","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/mds.27633","volume":"34","author":"CH Lin","year":"2019","unstructured":"Lin CH, Chen PL, Tai CH, Lin HI, Chen CS, Chen ML, Wu RM (2019) A clinical and genetic study of early-onset and familial parkinsonism in Taiwan: an integrated approach combining gene dosage analysis and next-generation sequencing. Mov Disord 34(4):506\u2013515","journal-title":"Mov Disord"},{"key":"1931_CR66","doi-asserted-by":"publisher","unstructured":"Simuni T, Brumm MC, Uribe L, Caspell-Garcia C, Coffey CS, Siderowf A, Alcalay RN, Trojanowski JQ et al (2020) Clinical and dopamine transporter imaging characteristics of leucine-rich repeat kinase 2 (LRRK2) and glucosylceramidase beta (GBA) Parkinson\u2019s disease participants in the Parkinson\u2019s progression markers initiative: a dross-sectional study. Mov Disord. https:\/\/doi.org\/10.1002\/mds.27989","DOI":"10.1002\/mds.27989"},{"issue":"4","key":"1931_CR67","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.ymgme.2019.10.001","volume":"128","author":"O Goldstein","year":"2019","unstructured":"Goldstein O, Gana-Weisz M, Cohen-Avinoam D, Shiner T, Thaler A, Cedarbaum JM, John S, Lalioti M et al (2019) Revisiting the non-Gaucher-GBA-E326K carrier state: Is it sufficient to increase Parkinson\u2019s disease risk? Mol Genet Metab 128(4):470\u2013475","journal-title":"Mol Genet Metab"},{"issue":"5","key":"1931_CR68","doi-asserted-by":"publisher","first-page":"e01281","DOI":"10.1002\/brb3.1281","volume":"9","author":"PC Hsieh","year":"2019","unstructured":"Hsieh PC, Wang CC, Tsai CL, Yeh YM, Lee YS, Wu YR (2019) POLG R964C and GBA L444P mutations in familial Parkinson\u2019s disease: case report and literature review. Brain Behav 9(5):e01281","journal-title":"Brain Behav"},{"key":"1931_CR69","doi-asserted-by":"publisher","unstructured":"Sanyal A, DeAndrade MP, Novis HS, Lin S, Chang J, Lengacher N, Tomlinson JJ, Tansey MG et al (2020) Lysosome and inflammatory defects in GBA1-mutant astrocytes are normalized by LRRK2 inhibition. Mov Disord. https:\/\/doi.org\/10.1002\/mds.27994","DOI":"10.1002\/mds.27994"},{"key":"1931_CR70","doi-asserted-by":"publisher","first-page":"101373","DOI":"10.1016\/j.scr.2018.101373","volume":"34","author":"N Gustavsson","year":"2019","unstructured":"Gustavsson N, Marote A, Pomeshchik Y, Russ K, Azevedo C, Chumarina M, Goldwurm S, Collin A et al (2019) Generation of an induced pluripotent stem cell line (CSC-46) from a patient with Parkinson\u2019s disease carrying a novel p.R301C mutation in the GBA gene. Stem Cell Res 34:101373","journal-title":"Stem Cell Res"},{"key":"1931_CR71","doi-asserted-by":"publisher","first-page":"101578","DOI":"10.1016\/j.scr.2019.101578","volume":"40","author":"E Rodriguez-Traver","year":"2019","unstructured":"Rodriguez-Traver E, Rodriguez C, Diaz-Guerra E, Arenas F, Arauzo-Bravo M, Orera M, Kulisevsky J, Moratalla R et al (2019) Generation of an integration-free iPSC line, ICCSICi005-a, derived from a Parkinson\u2019s disease patient carrying the L444P mutation in the GBA1 gene. Stem Cell Res 40:101578","journal-title":"Stem Cell Res"},{"key":"1931_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2019.01.023","volume":"127","author":"P Baden","year":"2019","unstructured":"Baden P, Yu C, Deleidi M (2019) Insights into GBA Parkinson\u2019s disease pathology and therapy with induced pluripotent stem cell model systems. Neurobiol Dis 127:1\u201312","journal-title":"Neurobiol Dis"},{"key":"1931_CR73","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.parkreldis.2018.08.023","volume":"64","author":"SJ Chung","year":"2019","unstructured":"Chung SJ, Jeon S, Yoo HS, Kim G, Oh JS, Kim JS, Evans AC, Sohn YH et al (2019) Detrimental effect of type 2 diabetes mellitus in a large case series of Parkinson\u2019s disease. Parkinsonism Relat Disord 64:54\u201359","journal-title":"Parkinsonism Relat Disord"},{"key":"1931_CR74","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.parkreldis.2018.05.026","volume":"55","author":"A Marques","year":"2018","unstructured":"Marques A, Dutheil F, Durand E, Rieu I, Mulliez A, Fantini ML, Boirie Y, Durif F (2018) Glucose dysregulation in Parkinson\u2019s disease: too much glucose or not enough insulin? Parkinsonism Relat Disord 55:122\u2013127","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"1931_CR75","first-page":"33","volume":"8","author":"A Konig","year":"2018","unstructured":"Konig A, Vicente Miranda H, Outeiro TF (2018) Alpha-synuclein glycation and the action of anti-diabetic agents in Parkinson\u2019s disease. J Park Dis 8(1):33\u201343","journal-title":"J Park Dis"},{"issue":"1\u20132","key":"1931_CR76","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0006-8993(96)00729-9","volume":"737","author":"R Castellani","year":"1996","unstructured":"Castellani R, Smith MA, Richey PL, Perry G (1996) Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 737(1\u20132):195\u2013200","journal-title":"Brain Res"},{"issue":"2","key":"1931_CR77","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s12035-012-8328-z","volume":"47","author":"E Guerrero","year":"2013","unstructured":"Guerrero E, Vasudevaraju P, Hegde ML, Britton GB, Rao KS (2013) Recent advances in alpha-synuclein functions, advanced glycation, and toxicity: implications for Parkinson\u2019s disease. Mol Neurobiol 47(2):525\u2013536","journal-title":"Mol Neurobiol"},{"issue":"10","key":"1931_CR78","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/mds.27132","volume":"32","author":"JP Trezzi","year":"2017","unstructured":"Trezzi JP, Galozzi S, Jaeger C, Barkovits K, Brockmann K, Maetzler W, Berg D, Marcus K et al (2017) Distinct metabolomic signature in cerebrospinal fluid in early Parkinson\u2019s disease. Mov Disord 32(10):1401\u20131408","journal-title":"Mov Disord"},{"key":"1931_CR79","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.nbd.2017.08.005","volume":"108","author":"A Biosa","year":"2017","unstructured":"Biosa A, Sandrelli F, Beltramini M, Greggio E, Bubacco L, Bisaglia M (2017) Recent findings on the physiological function of DJ-1: beyond Parkinson\u2019s disease. Neurobiol Dis 108:65\u201372","journal-title":"Neurobiol Dis"},{"key":"1931_CR80","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.freeradbiomed.2019.02.014","volume":"135","author":"N Sharma","year":"2019","unstructured":"Sharma N, Rao SP, Kalivendi SV (2019) The deglycase activity of DJ-1 mitigates alpha-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson\u2019s disease. Free Radic Biol Med 135:28\u201337","journal-title":"Free Radic Biol Med"},{"issue":"7","key":"1931_CR81","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41419-018-0749-9","volume":"9","author":"HJ Lee","year":"2018","unstructured":"Lee HJ, Yoon YS, Lee SJ (2018) Mechanism of neuroprotection by trehalose: controversy surrounding autophagy induction. Cell Death Dis 9(7):712","journal-title":"Cell Death Dis"},{"issue":"1","key":"1931_CR82","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41598-018-35811-8","volume":"9","author":"AC Hoffmann","year":"2019","unstructured":"Hoffmann AC, Minakaki G, Menges S, Salvi R, Savitskiy S, Kazman A, Vicente Miranda H, Mielenz D et al (2019) Extracellular aggregated alpha synuclein primarily triggers lysosomal dysfunction in neural cells prevented by trehalose. Sci Rep 9(1):544","journal-title":"Sci Rep"},{"issue":"12","key":"1931_CR83","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/glycob\/cwv091","volume":"25","author":"A Varki","year":"2015","unstructured":"Varki A, Cummings RD, Aebi M, Packer NH, Seeberger PH, Esko JD, Stanley P, Hart G et al (2015) Symbol nomenclature for graphical representations of glycans. Glycobiology 25(12):1323\u20131324","journal-title":"Glycobiology"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-020-01931-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-020-01931-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-020-01931-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T07:48:16Z","timestamp":1621496896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-020-01931-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":83,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1931"],"URL":"https:\/\/doi.org\/10.1007\/s12035-020-01931-4","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,20]]},"assertion":[{"value":"23 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All authors have no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}